Investors
Competitive advantages by "Choice and Concentration Strategy" tailored to the corporate development stages
Unlike other conventional biotech companies, DuChemBio has achieved a consolidated growth based on solid sales.
After securing cutting-edge manufacturing facilities and competent human resources,
DuChemBio has completed its own peculiar business scheme. It is expected to realize high profit from 2020.
※ Launching schedules for new drugs
F-DOPA
2019.12FES
Second half of 2020177Lu-DOTATOC
First half of 2021FACBC
Second half of 2021Contact support@duchembio.com to get more information